What is the recommended pneumococcal (Pneumococcal Conjugate Vaccine (PCV) and Pneumococcal Polysaccharide Vaccine (PPSV)) and influenza (Influenza Vaccine (IIV)) vaccine dosage schedule?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Pneumococcal and Influenza Vaccine Dosage Schedules

For adults, the recommended pneumococcal vaccination is a single dose of PCV20, which provides comprehensive protection against pneumococcal disease without requiring additional PPSV23 vaccination in most cases. 1

Pneumococcal Vaccine Recommendations for Adults

Adults ≥65 years of age

  • For those with no previous pneumococcal vaccination: Administer a single dose of PCV20 1, 2
  • For those previously vaccinated with PPSV23 only: Administer a single dose of PCV20 at least 1 year after the last PPSV23 dose 1, 2
  • Alternative schedule if PCV20 is unavailable: Administer PCV15, followed by PPSV23 at least 1 year later 3

Adults 19-64 years with immunocompromising conditions

  • For those with no previous pneumococcal vaccination: Administer a single dose of PCV20 3
  • For those previously vaccinated with PPSV23 only: Administer a single dose of PCV20 at least 1 year after the last PPSV23 dose 3
  • For those previously vaccinated with PCV13 only: Administer a single dose of PCV20 at least 1 year after the last PCV13 dose 3
  • Alternative schedule if PCV20 is unavailable: Administer PCV15, then PPSV23 at least 8 weeks later 3

Adults 19-64 years with chronic medical conditions

  • For those with no previous pneumococcal vaccination: Administer a single dose of PCV20 3, 1
  • For those previously vaccinated with PPSV23 only: Administer a single dose of PCV20 at least 1 year after the last PPSV23 dose 3, 1
  • For those previously vaccinated with PCV13 only: Administer a single dose of PCV20 at least 1 year after the last PCV13 dose 3

Special population: Hematopoietic Stem Cell Transplant (HSCT) recipients

  • Administer 3 doses of PCV20, 4 weeks apart starting 3-6 months after HSCT, followed by a fourth PCV20 dose at least 6 months after the third dose or at least 12 months after HSCT, whichever is later 1, 2

Influenza Vaccine Recommendations

Adults ≥9 years

  • Administer one 0.5 mL dose annually 4

Children 6 months through 8 years

  • If not previously vaccinated or unknown vaccination history: Two 0.5 mL doses administered at least 4 weeks apart 4
  • If previously vaccinated: One or two 0.5 mL doses (based on ACIP recommendations) 4

Children 6 months through 35 months

  • If not previously vaccinated or unknown vaccination history: Two doses (either 0.25 mL or 0.5 mL) administered at least 4 weeks apart 4
  • If previously vaccinated: One or two doses (either 0.25 mL or 0.5 mL) 4

Important Clinical Considerations

Timing of vaccination

  • Pneumococcal and influenza vaccines can be administered at the same visit at different anatomic sites 1
  • For patients who have received PCV15 but have not completed their series with PPSV23, one dose of PCV20 may be used if PPSV23 is not available 1, 2

Common pitfalls to avoid

  • Failing to check the patient's prior pneumococcal vaccination history can lead to incorrect vaccination schedules 1, 2
  • Not waiting the recommended interval between different pneumococcal vaccines (typically ≥1 year after PCV13 or ≥1 year after PPSV23) 1, 2
  • Withholding vaccination in the absence of an immunization record is not recommended; the patient's verbal history should be used to determine prior vaccination status 2

Special considerations for high-risk individuals

  • Adults with asplenia, complement deficiencies, or who work in outbreak settings are considered at increased risk for meningococcal disease and should receive appropriate meningococcal vaccination 3
  • Immunocompromised individuals may have a diminished immune response to vaccination 4
  • Recent evidence suggests that prior PPSV23 vaccination may diminish the response to subsequent PCV13 administration 5

Recent Updates

  • In October 2024, ACIP expanded recommendations to include a single dose of PCV for all PCV-naïve adults aged ≥50 years 6
  • The current recommendations represent a simplification of previous complex pneumococcal vaccination schedules 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.